See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
Tariffs
Liberation Day
Natural Disasters
Donald Trump
Social Media
Artificial Intelligence
Trade War
Baseball
Stock Markets
Education
Nintendo
Climate Change
Published • loading... • Updated

NG-350A Evaluated in FORTRESS Trial for Locally Advanced Rectal Cancer

Summary by curetoday.com
The first patient with locally advanced rectal cancer has been enrolled in the FORTRESS study which is evaluating the investigative immunotherapy NG-350A.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

All
Left
Center
Right
curetoday.comcuretoday.com

NG-350A Evaluated in FORTRESS Trial for Locally Advanced Rectal Cancer

The first patient with locally advanced rectal cancer has been enrolled in the FORTRESS study which is evaluating the investigative immunotherapy NG-350A.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

curetoday.com broke the news in on Thursday, April 3, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Cancer

Cancer

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.

News
For You
SearchBlindspotLocal